Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
News for Tenax Therapeutics, Inc. (TENX) centers on its progress as a Phase 3, development-stage pharmaceutical company focused on cardiopulmonary therapies. The company’s updates highlight the clinical and regulatory path of levosimendan, which it is developing for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a form of pulmonary hypertension for which Tenax states no product has been approved.
Investors following TENX news can expect regular coverage of clinical trial milestones, including enrollment updates, design details, and key analyses from the Phase 3 LEVEL and LEVEL‑2 studies of TNX‑103 (oral levosimendan) in PH-HFpEF. Press releases have described the blinded sample size re-estimation in LEVEL, the initiation of the global LEVEL‑2 study, and the company’s plans for an open-label extension study to provide continued access to TNX‑103 for trial participants.
Tenax news also includes intellectual property developments, such as the European Patent Office’s Intention to Grant a patent covering levosimendan and its active metabolites in PH-HFpEF, and Canadian patent progress for multiple levosimendan formulations and combinations with cardiovascular drugs. These items provide context on the company’s efforts to build long-term protection around its lead asset.
In addition, TENX news features financial results and corporate updates, reported through quarterly earnings press releases, as well as participation in healthcare and investor conferences and virtual KOL events focused on PH-HFpEF and levosimendan. For readers tracking the evolution of Tenax’s late-stage cardiopulmonary program, this news feed offers a consolidated view of trial progress, IP status, and corporate communications. Bookmark this page to follow ongoing disclosures related to TENX and its PH-HFpEF development strategy.
Tenax Therapeutics (TENX) announced the appointment of Robyn Hunter to its Board of Directors, effective January 28, 2022. Hunter, an independent director with extensive experience in development-stage biotechnology, will chair the audit and compliance committee. President and CEO Christopher T. Giordano expressed optimism about her contributions as the company advances its lead candidates, TNX-201 and TNX-102, into pivotal testing. Tenax focuses on treatments for cardiovascular and pulmonary diseases with high unmet needs.
Tenax Therapeutics (TENX) announced that the USPTO granted a patent for TNX-102, its subcutaneous formulation of levosimendan, aimed at treating pulmonary hypertension related to left heart failure (PH-HFpEF). The patent, issued on January 4, 2022, extends until at least 2039, allowing for treatment claims for various health conditions beyond PH-HFpEF. This development underscores the company's commitment to address unmet medical needs in cardiovascular diseases. Tenax plans to advance TNX-102 into pivotal Phase 3 testing based on encouraging clinical trial results.
Tenax Therapeutics (TENX) announced significant updates regarding its lead product candidates, TNX-102 and TNX-201. The company received a Notice of Allowance from the USPTO for patent claims on subcutaneous levosimendan, expected to be issued in January 2022, extending coverage until 2039. Additionally, TNX-103 successfully transitioned patients from IV to oral levosimendan, demonstrating comparable efficacy and safety. Tenax plans to initiate a Phase 3 study for TNX-201 in pulmonary arterial hypertension in the second half of 2022, supported by a new Scientific Advisory Board of experts.
Tenax Therapeutics, a specialty pharmaceutical company, reported its third quarter 2021 financial results. The company is advancing its clinical programs, initiating a pharmacokinetic study for its novel imatinib formulation, with a Phase 3 trial expected to start in Q2 2022. Tenax has received FDA clearance for its IND application and published findings on levosimendan's novel mechanism. Third quarter R&D expenses rose to $1.2 million, while G&A expenses increased to $2.6 million. The net loss was $3.8 million, with $8.4 million in cash as of September 30, 2021, expected to sustain operations until Q2 2022.
Tenax Therapeutics (NASDAQ: TENX) has received FDA approval for its Investigational New Drug (IND) application for a reformulated delayed-release imatinib for pulmonary arterial hypertension (PAH). The company aims to initiate a Phase 3 trial in Q2 2022 following a comparative pharmacokinetic study starting in October 2021. This new formulation seeks to mitigate gastric intolerance seen in prior studies, enhancing patient tolerance and potentially offering a disease-modifying treatment option for this critical condition.
Tenax Therapeutics, Inc. (NASDAQ: TENX) has announced a presentation at the virtual Benzinga Healthcare Small Cap Conference on September 29, 2021, at 1:35 p.m. ET. The company's focus is on developing therapeutics for cardio-pulmonary diseases. Attendees can register for the webcast here. Tenax is advancing a delayed-release formulation of imatinib for pulmonary arterial hypertension (PAH), expecting to commence a pivotal trial in 1H 2022. They also hold rights to levosimendan, demonstrating promising Phase 2 results in heart failure.
Tenax Therapeutics, Inc. (NASDAQ: TENX) has announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company specializes in therapeutics for cardio-pulmonary diseases. A pre-recorded presentation will be available for on-demand viewing starting September 13 at 7:00 A.M. (EST) on their website and through a provided webcast link. Tenax is advancing treatments like a delayed-release imatinib formulation and has acquired rights to develop levosimendan for pulmonary hypertension. More details can be found at tenaxthera.com.
Tenax Therapeutics (NASDAQ: TENX) reported its Q2 2021 financial results and highlighted progress in its clinical programs for pulmonary diseases. The company is advancing its imatinib program, which aims to improve treatment for pulmonary arterial hypertension, and the levosimendan study targeting pulmonary hypertension associated with left heart failure. Recent activities include a KOL webinar discussing levosimendan's potential and a publication regarding its mechanism of action. Financially, Tenax reported a net loss of $1.7 million, with $2.2 million in cash as of June 30, 2021. Following a recent equity offering, they anticipate sufficient funds through Q2 2022.
Tenax Therapeutics (Nasdaq: TENX) announced a significant publication about levosimendan, detailing its mechanism of action that improves cardiovascular hemodynamics in pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The publication reveals that levosimendan reduces stressed blood volume, leading to lower pulmonary wedge pressure and central venous pressure without inotropic effects. This positions levosimendan as the first therapy to enhance exercise capacity in PH-HFpEF. A Phase III study is expected to start in the first half of 2022.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a KOL webinar on Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) scheduled for August 16, 2021. KOL Daniel Burkhoff, M.D., Ph.D., will discuss treatment gaps and the potential of Levosimendan as a new therapy. Tenax's Chief Medical Officer, Stuart Rich, M.D., will outline the clinical development plan for Levosimendan, emphasizing its role as a first-in-class K-ATP activator. The event will include a Q&A session. Levosimendan has already shown potential benefits in clinical settings.